Refine
Year of publication
- 2024 (2)
- 2023 (14)
- 2022 (16)
- 2021 (11)
- 2020 (13)
- 2019 (17)
- 2018 (18)
- 2017 (12)
- 2016 (36)
- 2015 (30)
- 2014 (31)
- 2013 (29)
- 2012 (27)
- 2011 (28)
- 2010 (26)
- 2009 (24)
- 2008 (16)
- 2007 (20)
- 2006 (17)
- 2005 (20)
- 2004 (15)
- 2003 (14)
- 2002 (19)
- 2001 (18)
- 2000 (12)
- 1999 (16)
- 1998 (31)
- 1997 (25)
- 1996 (19)
- 1995 (36)
- 1994 (29)
- 1993 (21)
- 1992 (27)
- 1991 (15)
- 1990 (20)
- 1989 (20)
- 1988 (19)
- 1987 (16)
- 1986 (11)
- 1985 (7)
- 1984 (10)
- 1983 (10)
- 1982 (3)
- 1981 (3)
- 1980 (3)
- 1979 (8)
- 1978 (2)
- 1976 (2)
- 1975 (3)
- 1973 (2)
- 1972 (2)
- 1971 (2)
Document Type
- Article (597)
- Patent (117)
- Book (65)
- Conference Proceeding (34)
- Part of a Book (21)
- Report (5)
- Bachelor Thesis (3)
- Doctoral Thesis (3)
- Diploma Thesis (1)
- Preprint (1)
Language
- English (534)
- German (310)
- Multiple languages (2)
- Spanish (1)
Keywords
- Heparin (3)
- Bacillaceae (2)
- Biorefinery (2)
- Biotechnological application (2)
- Chemometrics (2)
- IR spectroscopy (2)
- NMR spectroscopy (2)
- Principal component analysis (2)
- Standardization (2)
- Subtilases (2)
- Subtilisin (2)
- bubble column (2)
- methanation (2)
- plug flow reactor (2)
- qNMR (2)
- (Poly)saccharides (1)
- (R)- or (S)- gamma-valerolactone (1)
- 4-hydroxy valeric acid (1)
- Algal Turf Scrubber (1)
- Algal–bacterial bioflm (1)
Institute
- Fachbereich Chemie und Biotechnologie (847) (remove)
NVS123 is a poorly water-soluble protease 56 inhibitor in clinical development. Data from in vitro hepatocyte studies suggested that NVS123 is mainly metabolized by CYP3A4. As a consequence of limited solubility, NVS123 therapeutic plasma exposures could not be achieved even with high doses and optimized formulations. One approach to overcome NVS123 developability issues was to increase plasma exposure by coadministrating it with an inhibitor of CYP3A4 such as ritonavir. A clinical boost effect was predicted by using physiologically based pharmacokinetic (PBPK) modeling. However, initial boost predictions lacked sufficient confidence because a key parameter, fraction of drug metabolized by CYP3A4 (ƒₘCYP3A4), could not be estimated with accuracy on account of disconnects between in vitro and in vivo preclinical data. To accurately estimate ƒₘCYP3A4 in human, an in vivo boost effect study was conducted using CYP3A4-humanized mouse model which showed a 33- to 56-fold exposure boost effect. Using a top-down approach, human ƒₘCYP3A4 for NVS123 was estimated to be very high and included in the human PBPK modeling to support subsequent clinical study design. The combined use of the in vivo boost study in CYP3A4-humanized mouse model mice along with PBPK modeling accurately predicted the clinical outcome and identified a significant NVS123 exposure boost (∼42-fold increase) with ritonavir.
Mannoheptulose is a seven-carbon sugar. It is an inhibitor of glucose-induced insulin secretion due to its ability to selectively inhibit the enzyme glucokinase. An improved procedure for mannoheptulose isolation from avocados is described in this study (based upon the original method by La Forge). The study focuses on the combination of biotransformation and downstream processing (preparative chromatography) as an efficient method to produce a pure extract of mannoheptulose. The experiments were divided into two major phases. In the first phase, several methods and parameters were compared to optimize the mannoheptulose extraction with respect to efficiency and purity. In the second phase, a mass balance of mannoheptulose over the whole extraction process was undertaken to estimate the yield and efficiency of the total extraction process. The combination of biotransformation and preparative chromatography allowed the production of a pure mannoheptulose extract. In a biological test, the sugar inhibited the glucokinase enzyme activity efficiently.